A First-of-its-Kind Event

A decade ago, when I served on the Breakthrough T1D International Board of Directors, I grumbled that most of the pioneering research we funded was revealed at the annual American Diabetes Association’s Scientific Sessions, making it seem as if ADA was driving all the exciting progress in the field. It drove me crazy. 

Crazy no more. 

On October 9, the doors of the Pennsylvania Convention Center in downtown Philadelphia opened for Breakthrough T1D’s first-ever Clinical and Research Congress. When I walked into the cavernous building, I thought I was in the wrong place. It seemed empty. Then I wandered into one of the three meeting rooms where sessions were underway, and in that moment, I knew everything had changed. 

Breakthrough T1D had laid down a marker. It was already the most important funder of T1D research. Now it was signaling to the world that it would also be the organization that brings scientists, patients, and clinicians together to accelerate progress toward curing and preventing T1D. 

Surrounded by the Best and Brightest in T1D 

Over the next two and a half days, I felt like I was surrounded by the Timothée Chalamets and Taylor Swifts of T1D. Look over there, it’s David Harlan, a longtime leader in diabetes research and clinical care at UMass Chan Medical School. Over there is Peter Senior, one of the pioneers of islet transplantation at the University of Alberta. Isn’t that Kimber Simmons, the pediatric endocrinologist at the Barbara Davis Center who is driving T1D screening? Is that Colin Dayan, the UK immunologist? And Belgium’s Chantal Mathieu, who has led the European diabetes research consortium? 

During the conference, I attended panels where I barely understood a word. It didn’t matter. I could feel the vibes rippling through the sessions among those who did understand the importance of what they were hearing. It was like sitting through an Italian opera: I didn’t understand most of the words, but I could feel the power of the voices, and that power lifted my spirits. In short, I lived off the buzz. 

An Electric Atmosphere 

What struck me most was the reaction among attendees. With the field now awash in T1D developments, from disease-modifying therapies to cell therapies to gene therapies and more advanced technology, seasoned, maybe even somewhat jaded scientists who go to literally half a dozen conferences a year were bubbling with excitement and energy. One person told me she attends many diabetes conferences around the world, and each time, in the weeks leading up to the event, she scours the program for T1D-related panels. “I started doing that a few weeks before this, and it hit me: it was ALL T1D and the challenge wasn’t finding something relevant but picking among so many compelling sessions.” 

An executive at a company working on T1D therapies told me they organized a dinner on Saturday night for 15 distinguished scientists. Normally, these dinners are social; people are exhausted from the day’s intense sessions. This one was the opposite. People wanted to keep talking about what they’d heard, and the dinner became an extension of the conference, with scientists exchanging ideas, discussing future collaborations, and sharing insights. Over and over, I heard the same refrain: “This is long overdue” or “This is the best T1D conference I’ve ever attended.” 

Talks that Left a Lasting Impression 

Two sessions stood out for me above all others. The first was Chantal Mathieu’s keynote. She talked about the benefits of T1D technology, the promise of disease-modifying therapies, the expansion of screening, and the potential to delay insulin dependence for years. But it was her ending that struck me. I know from my own research and writing that scientific collaborations aren’t easily forged. So much is at stake: credit, prizes, and financial rewards. Work is jealously guarded and parsimoniously shared. Chantal urged the audience to go down a different path. No single person, no single lab, no single company has the definitive answer, she said; the most groundbreaking science is done not in isolation but in collaboration. Speaking softly, but powerfully, she urged everyone to work together for a greater good: the health and welfare of the patients their work is intended to benefit. It was a powerful moment, and you could feel the room respond. 

The other exhilarating session was a debate between Colin Dayan and Peter Senior: “Disease modification vs. replacement therapy in T1D: Which strategy will be scalable, durable, and safe long term?” The two presented their arguments respectfully, with a bit of friendly needling. Colin said that emerging DMTs may allow for a one-and-done treatment, meaning they could be far more affordable and easily accessible, especially for children. DMTs also address the root cause of T1D from the start, rather than “putting a patch on it” later. Peter countered that far more people are living with established T1D than with early-stage T1D or a diagnosis less than 100 days old. For most of them, it is too late to preserve beta cells, so islet cell therapies, especially scalable manufactured versions, must be the solution. 

From Dreams to Concrete Possibilities 

But what struck me wasn’t who won the debate; it was that one could have the debate at all. A decade ago, DMTs were giant question marks and replacement therapies were still a dream. Today, there is one approved DMT and multiple cell therapies in human trials delivering promising results. A decade ago, this would have been a debate over dreams. In Philadelphia, it was a debate over concrete possibilities getting nearer and nearer to changing the lives of those with T1D forever. Whether you say that in Italian, English, or Latin, it makes my skin tingle. 

And it reinforces my certainty that my daughter Emma, now 40 and living with T1D for 26 years, will not live with this disease for the rest of her life. 

Breakthrough T1D’s first-ever Clinical & Research Congress (CRC 2026), focused entirely on type 1 diabetes (T1D), has come to a close! Check out all our coverage below from the exciting weekend in Philadelphia, PA, where researchers, clinicians, industry leaders, healthcare professionals (HCPs), and the T1D community united to share updates across our entire mission.

Check Out our CRC Recap Video!

Thanks for joining us throughout our coverage of our Clinical & Research Congress! And thank you to everyone who helped make this conference possible, including our sponsors, donors, supporters, and staff. We couldn’t do this without you.

We couldn’t be more proud of how our inaugural conference turned out, and we’re already looking forward to next year. Mark your calendars: CRC 2027 will take place in Washington, D.C., from October 15-17, 2027!

It’s a rainy day in Philadelphia, but the mood at CRC 2026 could not be sunnier! The attendees are positively buzzing (seriously) with how timely and impactful this meeting is. It’s the right time for a meeting focused exclusively on type 1 diabetes (T1D), and the good news is we won’t have to wait years for the next one!

CRC 2027 will take place from October 15-17 in Washington, D.C., USA. Stay tuned for more information!

Islet Cell Therapies vs. Disease-Modifying Therapies: Which is Better?

Spoiler alert: There’s no right answer—there are pros and cons to both!

Peter Senior, MBBS, Ph.D. (University of Alberta) and Colin Dayan, MBBS, Ph.D. (University of Birmingham) debated the safety, costs, monitoring, potential long-term outcomes, and considerations for global access of disease-modifying therapies (DMTs) versus islet cell therapies.

Dr. Dayan made the case that islet cell therapies may be effective in the short-term, but in the long-term they might not be scalable, affordable, or deliverable globally. On the flip side, emerging DMTs may allow for a one-and-done treatment—meaning they could be far more affordable and easily accessible, especially in the pediatric population. DMTs also address the root cause of T1D from the start, rather than “putting a patch on it” later.

On the flip side, Dr. Senior argued that there are significantly more people living with established T1D compared to early-stage T1D or even within 100 days of a diagnosis—meaning that islet cell therapies, especially manufactured versions that are scalable, must be the solution since it is too late to preserve beta cells in most people. He also made the point that islet cell therapies can give patients more beta cells than a DMT would—and more beta cells meanings better outcomes, including freedom and flexibility.

Someone in the audience chimed in with an important point: Ideally, DMTs and islet cell therapies can one day be combined to maximize the benefits of each (e.g., restore insulin production and address autoimmunity against beta cells).

Islet Cell Therapies

The Burden of Immunosuppression

Sabarinathan Ramachandran, Ph.D. (University of Minnesota) gave an update on immunosuppression with islet transplants. The key challenge is these transplants work, but over the long term, 50-70% of recipients lose function. He outlined the approaches investigators are taking to reduce the burden of these necessary drugs, like gene-editing, encapsulation, and engineered microenvironments.

Cellular Reprogramming

Hongkui Deng, M.D. (Peking University) presented a talk on cellular reprogramming, which involves treating cells with specific factors that turns them into a different cell type. Dr. Deng and his team developed a new, non-traditional strategy—which he called “chemical reprogramming”—that uses small molecules (instead of proteins) to reprogram cells. This approach is more efficient and easier to accomplish in the lab than traditional cell reprogramming approaches.

Using chemical reprogramming, Dr. Deng’s team turned a person’s fat cells into islet cells. The team then transplanted these islet cells back into the same person under the anterior rectus sheath, a large, easily-accessible, and well-vascularized area (meaning transplanted islets have access to blood vessels carrying nutrients and oxygen).

This person achieved substantial improvements in time in range and blood-sugar management, and no safety issues were identified during continuous monitoring. They were also already on immunosuppressants for a liver transplant. Now, more than one person has received this treatment, and Dr. Deng and his team are monitoring them closely.

Dr. Deng’s lab is also working on artificial intelligence (AI)-based approaches to scale up chemical reprogramming for islet cell therapies in addition to researching new ways to remove the need for immunosuppression.

Disease-Modifying Therapies

Clinical Trial Design Post-Teplizumab

• Presenter: Jason Gaglia, M.D. (Joslin Diabetes Center, Harvard Medical School)
• We know that teplizumab (Tzield) works, but individual responses can be variable and there may be an optimal treatment window.
• Now that we have an approved DMT, the question becomes: Do we use teplizumab as a comparator in clinical trials instead of a placebo, so that everyone who participates has a chance to benefit?
• If we do, people may not want to participate if they can get teplizumab at their clinic and covered by insurance—or they may not want teplizumab at all because of the 14-day infusion, side effects, or other reasons.
• With this in mind, we do not have a clear answer yet about whether teplizumab should be used in place of a placebo in DMT clinical trials.

Early Detection

Advanced Screening Technologies

Katsiaryna Prystupa, M.D. (German Diabetes Center) presented a machine learning analysis to sort more than 600 newly diagnosed people with T1D into three groups based on shared features like autoantibodies and insulin resistance. One group is associated with diagnosis earlier in T1D progression, when more beta cells are remaining. This work could help identify who may benefit most from DMTs.  

Callie Zaborenko, Ph.D. (Indiana University School of Medicine) analyzed electronic health record (EHR) data and genetic information from adults to see whether a genetic risk score could help identify people at a higher risk of developing T1D. Adults with the highest scores were nearly ten times as likely to be diagnosed with T1D as adults with mid-range scores. This could one day help guide who is offered autoantibody testing, though more research is needed first.

Alice Carr, Ph.D. (University of Alberta) talked about the best way to assess if DMTs are working in early-stage T1D trials. Using data from TrialNet and TEDDY studies, she presented her work showing that oral glucose tolerance tests (OGTT) can estimate insulin secretion as a measure of beta cell responsiveness. This may better capture risk of T1D progression, which can help researchers choose the best participants for DMT clinical trials and understand if DMTs are working.

Kathleen Gillespie, Ph.D. (University of Bristol) and her team screened nearly 20,000 adults for islet autoantibodies and followed those with confirmed autoantibodies in the T1DRA study. The prevalence of adults who had multiple autoantibodies was similar to that in children, which supports screening in adults. The team is developing an approach to group people with a single autoantibody into tiers based on progression risk, which could help tailor individualized monitoring.

Brittany Bruggeman, M.D. (University of Florida) analyzed the TEDDY study to better understand the decline in function in the part of the pancreas that helps digest food (the exocrine pancreas) in children at risk for T1D. In kids who developed islet autoantibodies earlier, a biomarker of exocrine pancreatic function (FE-1) was lower in infancy, before autoimmunity against beta cells. Combined with other tests, this biomarker may one day help researchers better predict T1D progression.

Medical Affairs

Communication and Shared Decision-Making: Old and New Challenges in T1D

The diabetes care team is made up of many disciplines. This session was presented by three psychologists and a physician focusing on the behavioral and educational aspects of T1D.

The first speaker, Ellen O’Donnell, Ph.D. (MassGeneral Brigham and Harvard Medical School) discussed the best communication tactics for children and adults in early-stage T1D. Telling a person, and their family, about an early-stage T1D diagnosis is a life-changing conversation. Thankfully, we know the best ways to communicate this information: using metaphors, graphics, and pictures, and taking into account the full context of the family (e.g., their family structure, experience with T1D, and baseline mental health). Not only do we know the best ways to have these conversations, but there are tools and resources for clinicians and healthcare providers.

Next up, Jane Speight, Ph.D. (Deakin University, Australia) talked about a topic that we need to dedicate more time to: diabetes stigma. T1D is a chronic illness, and living with it is a deeply emotional experience. When HbA1c stops being information and starts being a measure of self-worth, it has negative results. It can cause teens, parents, and adults with T1D to feel dehumanized, which has a direct result on physical and mental health.

Some alarming stats:

Diabetes stigma is associated with lower well-being and less confidence (self-efficacy) in managing diabetes, in addition to other worse outcomes:

But there is something we can do. A positive, self-fulfilling feedback loop predicated on stigma-free communications can help people do better—and this needs to be considered in every conversation.

The final speaker, Carol Levy, M.D. (Icahn School of Medicine at Mt. Sinai) got into pregnancy and T1D. We know that women with diabetes require much tighter targets to reduce maternal and fetal health risks. These risks are real and difficult to manage for the mother and the physician—and they start pre-conception and continue post-partum. Insulin requirements change dramatically throughout gestation, and there is limited real estate on the body for continuous glucose monitors (CGMs) and insulin pumps. Even with the better tools that we have today, pregnancy outcomes remain suboptimal.

The main point: Flexibility, creativity, and understanding are needed. Pregnant women are thinking about lots of things—not just their T1D management. They don’t all want to wear a pump.

Centers of Reference

Breakthrough T1D Chief Medical Officer International, Thomas Danne, M.D., Ph.D. has a very clear way of describing our challenge for the future. Cures for T1D are planes, in the air. We’re still building the plane, but it’s in the air right now. We must ensure there is a runway so that when the plane is ready to land, it can.

Right now, we’re building that runway through our Centers of Reference program, which is explored in a presentation by James Shaw, M.D. (Newcastle University).

Centers of Reference are expert multidisciplinary T1D care centers that are preparing healthcare professionals (HCPs) around the world to administer manufactured islet cell therapies to people with T1D. The goal is to make sure that expert clinical teams—who are already doing islet cell transplants at low scale—are ready to integrate these therapies into clinical practice at their institutions and train others, once they have regulatory approval.

Breakthrough T1D has created several working groups to help move these therapies forward now so they’re ready when cell therapies are (at scale). These include:

1. Training and education, including a clinician training program launched with ATTD in Europe and the American College of Diabetology in the US.
2. Clinical access, including reaching community clinicians, countering myths and fears, and peer review between Centers.
3. Harmonizing clinical care, including team composition, patient screening, monitoring, and follow-up.
4. Benchmarking and validation, including quality-assured registries and peer review.

Centers of Reference are a work in progress. They’re going to take time to get off the ground—but all the right people are working on it today.

That’s a wrap on CRC 2026! Keep an eye out for one more recap tomorrow with everything you need to know about this inaugural conference.

This article was written by Sandy Vogt, Ph.D. and Brian Herrick.

We are two days into the first ever Breakthrough T1D Clinical & Research Congress! Day 1 was full of optimism and excitement about the meeting—it’s really ALL type 1 diabetes (T1D), which is unique—and the future of treatments and therapies for this community.

Peter Senior, MBBS, Ph.D. (University of Alberta), a longtime Breakthrough T1D-funded collaborator, spoke at the beginning of the first session and his comments really set the tone for the day.

CRC is 100% Focused on the Lived Experience

A guiding principle of this meeting is that it is centered around the lived experience of people with the disease. To drive this home, all of the parallel sessions were introduced by community members, sharing a story about their lives with T1D.

One video focused on how artificial intelligence (AI) has the potential to transform diabetes technology—fewer calculations means less daily burden. Here’s another perspective from Daniel Newman:

That’s our whole goal: people doing better. And CRC was filled with nearly 1,000 people—all of whom are working toward that shared goal.

With that in mind, let’s hear about the solutions, innovations, and cutting-edge work shared on day 2! As a reminder, every session is not included here—and we encourage you to attend next year to get the full CRC experience!

Check out our video recap of CRC 2026 day 2!

Unmet Needs: Where We Are and What’s Still Needed for People with T1D

The day kicked off with a symposium sponsored by Vertex Pharmaceuticals that explored the unmet needs and emerging treatments in T1D. Vertex is developing a manufactured islet cell therapy for T1D, which is currently in a phase 1/2/3 clinical trial. Jennifer Sherr, M.D., Ph.D. (Yale School of Medicine) and Dr. Peter Senior shared a wealth of data showing that outcomes have been improving for people with T1D year by year with new technology, primarily automated insulin delivery (AID)—but people still aren’t doing well enough. Even with the best technology, a study showed that a significant percentage of people still aren’t achieving ideal glycemic control, and some are still experiencing severe hypoglycemic events.

In summation: Technology has absolutely improved care, but there are still unmet needs to be addressed.

Islet Cell Therapies

Protecting Transplanted Islets

The first islet cell therapy session of the day, chaired by Valeria Sordi, Ph.D. (IRCCS Ospedale San Raffaele), focused on how we can take manufactured islets and keep them safe from the immune system post-transplant without the need for immunosuppression. Islet cell therapy is a promising treatment for T1D but there are major barriers—one of which is the requirement for immunosuppression. This session tackled tactics for removing that barrier.

Juan Alvarez-Dominguez, Ph.D. (University of Pennsylvania) presented how he and his team developed a method to watch the cells mature by placing electrodes inside the lab-grown islets. They have learned that the cells mature very quickly—like a switch being flipped on—versus gradually.

Audrey Parent, Ph.D. (University of California, San Francisco) and Sonja Schrepfer, M.D., Ph.D. (Cedars-Sinai Medical Center) both tackled gene editing using different approaches. Dr. Parent focused on modifying existing cells to protect them from the autoimmune response while Dr. Schrepfer’s work was centered on making the transplanted cells immune-evasive. These two tactics can potentially be used together in a complementary manner.

Zimislecel: Meaningful Benefits for Participants

Michael Rickels, M.D. (University of Pennsylvania) gave an update on the clinical trial for Vertex’s manufactured islet cell therapy zimislecel. All 12 participants have improved blood-sugar levels and no severe hypoglycemic events, and 10 of 12 people are off external insulin. Participants report significantly less diabetes distress and fear of hypoglycemia, demonstrating that islet cell therapies like this have a real impact on the day-to-day experiences of living with T1D.

Disease-Modifying Therapies

Research Supported by the T1D Fund

William Quinn, Ph.D. (SAB Bio) presented phase 1 clinical data from four people treated with SAB-142 (humanized ATG), a DMT designed to delay or prevent progression of T1D. The therapy targets immune cells responsible for the destruction of insulin-producing beta cells while also preserving those that help balance the immune system. SAB-142 has a favorable safety profile and preserved C-peptide in all participants—while actually enhancing C-peptide in 3 of 4 people. Enrollment is ongoing for the SAFEGUARD clinical trial for people within 100 days of a T1D diagnosis, and next up is the Breakthrough T1D-funded PRISE-ATG study, led by Dr. Haller, which will study SAB-142 in people within two years of a diagnosis.

Taylor Triolo, M.D. (Barbara Davis Center for Diabetes) presented safety data around CNP-103, a DMT in clinical trials developed by COUR Pharmaceuticals. CNP-103 works by restoring balance to the immune system by training it to stop recognizing beta cells as a threat. In a study with 32 participants, early data show favorable safety and tolerability, with no severe adverse events. The trial is expanding and efficacy data is expected in late 2026 or 2027.

Early Detection

A session chaired by Linda DiMeglio, M.D. (Indiana University School of Medicine) tackled early risk assessment for T1D. How do we find people earlier? How can we ensure they are able to take advantage of the myriad benefits of knowing they have early-stage T1D?

First up, Andrea Steck, M.D. (University of Colorado) talked about using continuous glucose monitoring (CGM) to assess T1D risk in addition to family history and autoantibody results. And there are some specific findings on how these can be used together:

• More time above 140 mg/dl is indicative of disease progression.
• Individuals who spend more than 15% of the day above 140 had about a 60% chance of progressing to stage 3 T1D within two years, versus about 15% for those below that level.
• Combined tools improve prediction validity. A risk score using CGM data, HbA1c, family history, and autoantibody results sorted people into low risk (about 5% chance in two years), medium (13%), and high (48%).
• For children in the middle stage, spending over 10% of the time above 140 signals risk of progression, and over 20% means it’s time to evaluate for stage 3 T1D.

Last up was Greg Lipak (HealthShare Exchange), who discussed how we can use AI to find individuals who may be misdiagnosed in electronic health records.

Improving Lives

Diabetic Ketoacidosis (DKA): Transforming Care with Continuous Ketone Monitoring

• Presenters: Richard Bergenstal, M.D. (HealthPartners Institute), Jennifer Sherr, M.D., Ph.D. (Yale School of Medicine), and Medha Munshi, M.D. (Harvard Medical School); supported by Abbott
• DKA is still a risk for people of all ages living with T1D because available ketone measurement methods are not widely used—and this drives up healthcare costs.
• Dual glucose-ketone monitoring will help guide care in real-time, warning people in advance so they can take action before an emergency happens.
• This technology could be particularly transformative for families, young adults transitioning to independence, people taking SGLT inhibitors, and older adults with other conditions or cognitive decline.

In a session chaired by Viral N. Shah, M.D. (Indiana University School of Medicine) that spanned multiple topics, Kalie L. Tommerdahl, M.D. (University of Washington) presented research on obesity and kidney disease in youth with T1D. Her data suggested that obesity and glycemic control affect T1D kidney health independently, which supports the notion that both need to be addressed in people with T1D for the best possible kidney outcomes.

Advocacy

Expanding Global Access to T1D Treatments and Care

• Professor Partha Kar (Portsmouth Hospitals NHS University Trust) talked about improvements in access to T1D care in India, ranging from education, to insulin, to glucose testing strips. Renza Scibilia (Senior Director of Global Responsibility) also mentioned the key role of Breakthrough T1D in advocating for better access, psychosocial health, and more.
• Carlos Antillón, M.D. (CEDYN, Mexico) presented on how global access and T1D innovations must advance together, and clinicians can help overcome barriers through advocacy, evidence generation, personalized treatment, HCP and patient education, and understanding what patients can realistically afford and sustain.
• Princess Padmaja K. Parmar (The Friends of Mewar) gave an inspiring talk on how global access to T1D supplies must be dependable and how lived experiences should guide all future work around T1D. She also highlighted the role of Breakthrough T1D in advancing research and access on a global scale.
• David Beran, Ph.D. (University of Geneva) gave a presentation around how barriers to access to T1D therapies and devices persist worldwide due to product shortages or discontinuations, with challenges in low- to middle-income countries largely driven by supply chain issues, technology costs, and more. Global advocacy and policy changes can help overcome these barriers.

Medical Affairs

Enrolling in Clinical Trials

Kimber Simmons, M.D. (University of Colorado) hit on a key point (and Breakthrough T1D organizational priority): clinical trial recruitment.

It is well established that clinical trials take far too long to enroll. It is also true that a new T1D diagnosis is an incredibly difficult situation for families to navigate. They must weigh placebo, randomization, side effects, and more. Then, the family has to make a decision quickly to successfully enroll within the clinical trial window.

Dr. Simmons and her team in Colorado rolled out a program to educate families about beta cell preservation in their one-week follow-ups. The results were striking. Among interested families, 24% of families enrolled in a clinical trial within 8 weeks.

Healthcare Professionals with T1D: A Unique Perspective on T1D Care

• Andrew Welch, M.D. (University of Cincinnati) talked about disruptions in diabetes supplies, including two calls to action: 1) diabetes tech companies should give people the quantity of supplies they actually need, taking into account early failures and 2) we need transparent real-world data about supply interruptions and their consequences.
• Sarah Westen, Ph.D. (University of Florida) and Marissa Hitchcock, BSN, RN, CDCES (Children with Diabetes) discussed how language matters when talking to people with T1D, especially when it comes to communicating the risk of complications and reducing diabetes stigma. Dr. Westen also told her own T1D story, including how Breakthrough T1D has supported her personally—and professionally!
• Kathryn Nagel, M.D. (Maine Medical Center) presented on how we need more data and better care for women with T1D who are pregnant, especially through psychosocial support and technologies for pregnancy-specific glycemic goals.

Look out for another article coming soon covering day 3 of CRC 2026. Keep an eye on our News & Updates webpage!

This article was written by Sandy Vogt, Ph.D., and Brian Herrick.

Hello from Philadelphia, PA! We could not be more thrilled that, after years and years, we have finally kicked off our inaugural Breakthrough T1D Clinical & Research Congress (CRC). This groundbreaking event is focused entirely on type 1 diabetes (T1D), and it’s happening right now!

For the next three days, we’ll provide you with everything you need to know about this conference, the top takeaways, and what the path forward looks like so that people with T1D can live better, healthier lives. And in case you missed it, check out our precap on what we plan to cover.

Check out our video recap of CRC 2026 day 1!

Islet Cell Therapies: Research Supported by Breakthrough T1D or the T1D Fund

Piotr Witkowski, M.D., Ph.D. (University of Chicago) presented on the Breakthrough T1D-funded clinical trial for tegoprubart, an alternative to standard immunosuppressants, developed by T1D Fund company Eledon. Tegoprubart is maintaining its success: All 12 participants who have received an islet cell transplant are off external insulin (7 after one transplant; 5 after two) with stable blood-sugar levels, no side effects, and no toxicity in the kidneys. An upcoming clinical trial will test tegoprubart in people with T1D and chronic kidney disease (CKD)—the first time this population is eligible for an islet cell therapy.

Per-Ola Carlsson, M.D., Ph.D. (Uppsala University) provided an update on the first person treated with a partial dose of immune-evasive islet cells developed by Sana, another T1D Fund company. There were no serious side effects, and the cells continue to survive and make insulin over a year post-transplant.

Leonardo Velazco-Cruz, Ph.D. (Century Therapeutics, a T1D Fund company) presented on a manufactured immune-evasive islet cell therapy that has shown promise in animal models of T1D, advancing towards first-in-human studies and clinical-grade, scalable manufacturing. Unlike other therapies currently in clinical trials, Century’s product is both scalable and does not require immunosuppression.

Disease-Modifying Therapies

C-peptide: Why it Matters for Clinical Outcomes

• Presenter: Justin Gregory, M.D. (Sanofi)
• Based on several datasets, we know that more C-peptide means better glycemic control and fewer short- and long-term complications (especially severe hypoglycemia, diabetic ketoacidosis, and retinopathy).
• This relationship is foundational to why we are so focused on C-peptide: it matters!
• For years, Breakthrough T1D has advocated for the use of C-peptide as a validated surrogate endpoint, which would make DMT clinical trials smaller, faster, and less expensive—without cutting corners on safety.

Early Detection

The benefits of screening for T1D are well established. Combined with follow-up and monitoring, early detection can reduce the risk of diabetic ketoacidosis (DKA) at diagnosis, connect people to clinical trials and specialists, open the door to FDA-approved therapies that can delay the need for insulin therapy, and give families time to plan and prepare.

The question now is how to increase access to screening, and how to ensure people with early-stage T1D are connected to next steps and options. That was the focus of a panel chaired by Chantal Mathieu, M.D., Ph.D. (KU Leuven, Belgium).

Improving Lives

Kerendia (Finerenone): First New Therapy in 30 Years for Kidney Disease and T1D

• Presenter: Sergio Chang Figueroa, M.D. (University of Louisville), speaking on behalf of Bayer
• The FDA recently approved finerenone (brand name Kerendia), a once-daily pill already approved for type 2 diabetes, for people with T1D and CKD—the first advance in nearly 30 years for this population.
• CKD is one of the most common complications of T1D: nearly a third of people with T1D will develop it, increasing their risk of kidney failure and heart complications.
• As part of our Improving Lives program, Breakthrough T1D strategically collaborated with Bayer to support the FINE-ONE clinical trial that led to this approval.

Making Sure Your Insulin is Still Potent

• Presenter: Maren Schinz, Ph.D. (Beyond Diagnostics AG)
• People living with T1D may wonder if their insulin is still good to use after temperature changes—and this company is developing a way to fix that.
• Studies in animal models of T1D have shown that injecting insulin that has lost some of its potency doesn’t lower blood-sugar levels as well.
• This team developed an assay that can be paired with a smartphone to check the potency of insulin in real-time.

Automated Insulin Delivery (AID) in the Era of Artificial Intelligence (AI)

• Tadej Battelino, M.D., Ph.D. (University Medical Center Ljubljana) talked through use of AI in continuous glucose monitor (CGM) data, MRIs, and other clinical metrics to predict progression or monitor the impacts of T1D.
• Todd Brusko, Ph.D. (University of Florida) highlighted complex data types generated from human samples that can be analyzed with AI to help us learn even more about what causes T1D.
• Juan Espinoza, M.D. (Northwestern University) highlighted how to best integrate AI into T1D care in clinical settings.
• Boris Kovatchev, Ph.D. (University of Virginia) presented about how digital twins—a computational model for blood-sugar changes—fueled by AI can speed clinical development of next-generation AID systems.

Medical Affairs

As early detection, disease-modifying therapies, and islet cell therapies move forward and treatment options expand, Tandy Aye, M.D. (Stanford School of Medicine), Brynn Marks, M.D. (Senior Director of Medical Affairs at Breakthrough T1D), and Katelyn O’Brien, Pharm.D. (Boston Medical Center) participated in a session chaired by Bobby Gabbay, M.D., Ph.D. (Joslin Diabetes Center) about how the medical community needs to effectively adapt to the current and future state of T1D care.

Some high-level takeaways:

• The field is moving faster than the care system. The world of T1D is rapidly changing. The paradigm is changing, including the proliferation of screening and early detection and novel disease-modifying therapies and islet cell therapies. Clinical teams must be ready to keep pace with the current and future landscape.
• Islet cell therapies are coming—and they depend on workforce as much as science. There are severe limits to the supply of deceased donor islets (for now!) but there also aren’t enough care teams to administer them. Learn more about how we’re trying to solve this problem through Centers of Reference and Breakthrough T1D’s Interventional Diabetology program.
• Diabetes care and education specialists are an underused bridge. Fewer than 5% of Medicare beneficiaries and fewer than 7% of privately insured people get education in the first year after diagnosis. These specialists have longer visits, can close technology gaps (CGM, automated insulin delivery), and relay real-world challenges back to clinicians.
• The workforce pipeline is a concern. We need more endocrinologists.

Kick-off

Dr. Mathieu closed the Congress’s opening day by describing the future of T1D as “two paths.” One is technology, and one is disease-modifying therapies plus islet cell therapies. These are not two disparate paths—technology has the capability to keep people healthy so that when DMTs and islet cell therapies arrive at scale, people with T1D can make the most of it.

Where we are

• Technology works in the real world. Dr. Mathieu presented data from her homeland of Belgium showing HbA1c falling year over year, first with sensors (around 2017) and further with hybrid closed-loop systems. In addition to glycemic improvements, people with T1D are seeing lower risk of complications, including retinopathy and kidney disease.  
• Disease-modifying therapies are here. Teplizumab, approved in November 2022, is the first therapy to delay the immune attack on beta cells. It has since expanded to children as young as one and to many countries.
• Screening is rapidly ramping up. Dr. Mathieu’s European consortium has screened about 140,000 children—and this is only increasing in Europe and across the world.

Our vision for the future

• Treat earlier in stages 1 and 2, to delay insulin therapy dependence by months, years, or decades.
• Personalize treatment using immune biomarkers that predict who will respond.
• Run more trials and build more integrated networks, like TrialNet.
• Islet cell therapies are next.

The last thing she said, and a key theme of this meeting, is the need for collaboration. We all need to set our egos aside and work together. The people in this room are responsible for the current state—and the myriad revolutions that have directly led to people with T1D doing better today. The people in the room are going to be the ones that make cures possible—but only if we work together.

Look out for articles coming soon covering days 2 and 3 of CRC 2026. Keep an eye on our News & Updates webpage!

This article was written by Sandy Vogt, Ph.D., and Brian Herrick.

After months and months of preparation, it’s finally here! Breakthrough T1D’s very first Clinical & Research Congress (CRC), a groundbreaking event focused entirely on type 1 diabetes (T1D), is happening this week from October 9-11 in Philadelphia, PA.

Bringing Together People United in Our Shared Goal

This scientific meeting is a groundbreaking event, uniting T1D researchers, scientists, healthcare professionals (HCPs), industry leaders, and community members from all parts of the globe, whose lives have been shaped by T1D in one way or another. Attendees will have the chance to discuss cutting-edge advancements in T1D discovery science, technology, treatments, and more. Our agenda is shaped by the voices of the T1D community, ensuring that the lived experience of T1D is at the center of the ongoing work toward our shared goal: improve the lives of people with T1D as we drive toward cures.

The CRC will be hosted in Philadelphia, where Breakthrough T1D was founded 50+ years ago. Philadelphia is a hub of medical innovation and scientific advancements, making it an ideal location for experts from across the world to convene and share T1D research, clinical progress, and milestones.

What We’re Looking Forward To

Cures

• Progress in several islet cell therapy studies we’re watching closely
• Novel strategies to protect transplanted islets
• New approaches in disease-modifying therapies (DMTs) and developments in ongoing clinical studies
• Expert perspectives on general population screening for T1D
• The role of genetic risk and other advanced technologies for T1D early detection

Improving Lives

• Recent exciting progress in T1D complications, including chronic kidney disease
• Progress in automated insulin delivery and the role of artificial intelligence
• Advancements in ketone monitoring and management
• Innovations in adjunctive therapies

Advocacy and Medical Affairs

• Developments in expanding global access to life-changing treatments
• Insights into gaps in T1D clinical care—and how we can fill them
• Strategies for clinical trial education and awareness
• Perspectives on clinical trials, pregnancy, technology, and more from HCPs living with T1D
• Discussions around scaling up islet cell therapies from a clinical perspective

CRC: A Place to Come Together to Share T1D Breakthroughs

We envision this event as the go-to forum for translational updates, collaborative dialogue, and cross-sector collaboration. Our leadership and staff have worked tirelessly for months on end to bring this vision to life, and many will be in attendance participating in sessions, sharing ideas, and making sure the event runs smoothly from start to finish.

Updates Coming Your Way – Stay in the Know

This is the first time in history Breakthrough T1D is hosting an event like this (and it won’t be the last!). We are thrilled to create a one-of-a-kind space where researchers and T1D community members from around the globe can connect, collaborate, share ideas, and ultimately contribute to our shared mission of a world without T1D. We can’t wait to share the exciting updates we’ll hear at CRC with our community. Thank you to our supporters for helping make this event possible. We wouldn’t be able to do this without you!

Islet cell therapies for type 1 diabetes (T1D) are in the works. In clinical trials, people are coming off external insulin—and experiencing healthy blood sugar levels. Researchers and clinicians are working hard behind the scenes to advance next-generation manufactured islet cell therapies as scalable cures. The momentum is real—and it’s more important than ever to double down, bring all the key players together, and make them a reality.

The Workshop: Bringing Together Key Voices

To keep the momentum going, Breakthrough T1D co-hosted a public workshop with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) titled “Accelerating the Translation of Cell Therapy for Type 1 Diabetes.” This workshop convened researchers, clinicians, industry leaders, representatives from the U.S. Food and Drug Administration (FDA), individuals with T1D, and more to discuss best practices and recommendations for accelerating islet cell therapies for the T1D community as newer generations become available.

The planning committee included several Breakthrough T1D staff:

• Esther Latres, Ph.D. (Senior Vice President, Research)
• Nicholas Mamrak, Ph.D. (Senior Scientist, Research)
• Marjana Marinac, Pharm.D. (Associate Vice President, Regulatory Affairs)
• Chanel Press, Ph.D. (Director, Regulatory Affairs)
• Brianna Greeno (Senior Manager, Regulatory Affairs)

The Conversation: Advancing Islet Cell Therapies from the Lab to Humans

The workshop broadly focused on considerations for advancing manufactured islet cell therapies, including lab-based work, large-scale manufacturing, and clinical trial design. Read on to learn more about the discussion around each topic.

Why this Matters

Islet cell therapy science is advancing on three fronts at once: nonclinical research in the lab, clinical trials in humans, and large-scale manufacturing. While researchers, scientists, and clinicians are working hard pushing these efforts forward, Breakthrough T1D is helping to keep the conversation open around what’s working, how to overcome challenges, how to engage with regulators, and new partnerships and collaborations. Even more, keeping the voices of people with T1D in the mix is key to advancing islet cell therapies in a way that’s meaningful for our community. Breakthrough T1D thanks the NIDDK for co-hosting a successful event and all presenters, panelists, and attendees for contributing to critical conversations that will ultimately help accelerate next-generation islet cell therapies for type 1 diabetes.

New Publication Alert!

Breakthrough T1D spearheaded a paper titled “International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes” that was published in Diabetologia. This is an important step toward integrating general population screening for type 1 diabetes (T1D) into clinical practice globally. Read on to learn more about why this is important, what experts think this should look like, and what it means for you and your family.

Making the Case for General Population T1D Screening

In 2024, Breakthrough T1D led the way with the publication of Consensus Guidance for Monitoring Persons with Islet Autoantibody-Positive Pre-Stage 3 Type 1 Diabetes, which lays out what clinicians should do when T1D autoantibodies are detected. But it does not touch on the bigger question: who should get screened?

There is an urgent need for population-level screening because:

• Global T1D incidence is increasing.
• Early detection has substantial benefits.
• Most T1D diagnoses occur in people without any family history of the disease.
• Evidence from ongoing, large-scale studies around the globe has shown that we have a screening method that works.

Breakthrough T1D convened a group of nearly 30 international experts to establish consensus that can act as a clinical roadmap to make general population screening a reality.

Key Recommendations for Clinical Adoption of General Population T1D Screening

So, who should get screened? Experts recommend that T1D screening begin in young children aged 2-4 years, with rescreening of children who test negative at ages 6-8 years and again at 10-15 years, aligned with other preventative healthcare visits. Every initial screening result should be confirmed with another test before diagnosis.

This may seem simple enough, but integrating screening into established clinical workflows will require collective effort. Healthcare systems must be fully prepared to deliver the entire screening, monitoring, and referral pathway before widespread integration. Policy and infrastructure must be in place, including established processes for confirming test results, education and monitoring of people with early-stage T1D, and referring people to specialists. In addition, healthcare professionals (HCPs) will need to effectively communicate with and provide psychosocial support to families at every step of the screening process.

The bottom line is that integrating general population T1D screening into clinics will require extensive cooperation across diverse medical settings to become a reality. But the payoff is clear: combined with Tzield and other emerging DMTs, general population screening should open the door to delaying—and eventually preventing—the onset of clinical, stage 3 T1D.

What this Means for You and Your Family

Right now, children and adults with or without a family history of T1D can participate in screening through free, research-based programs like TrialNet and ASK. Screening can be done in-person at certain locations, or screening kits can be sent straight to your home.

Based on the consensus guidance, families may consider starting to screen their children as early as ages 2-4. If the screening test detects autoantibodies, there are now concrete next steps that families can discuss with their physicians. You don’t have to wait until general population screening is integrated into clinics to take advantage of it.

Screening and Early Detection are Key to Breakthrough T1D’s Mission

General population T1D screening is a key part of our mission strategy, and more people screening means more people experiencing the benefits of early detection. To screen as many people as possible, clinicians need guidance—and this publication provides just that. We now have concrete recommendations for who to screen for T1D and when. Even more, this consensus has been signed off by almost every single one of our peer institutions, amounting to 20 global diabetes societies and organizations.

This publication is bringing conversations around general population T1D screening to the forefront. Breakthrough T1D is committed to expanding T1D early detection on a global scale, and widespread screening is one of our top priorities. We are mobilizing our resources, knowledge, and partnerships to make this a reality sooner so that more families around the world can benefit.

To accomplish our mission of a world without type 1 diabetes (T1D), one thing is clear: the more minds we have thinking about T1D, the better. That’s why Breakthrough T1D brings in interns each year, including in our Research department. Training the next generation isn’t just about career development—it’s about fresh eyes, new ideas, diverse expertise, and encouraging interest in our common goal.

Our 2026 interns have come from diverse backgrounds, each bringing a unique perspective to the teams and projects which they contributed to over the summer. From business development, to funding landscapes, to literature reviews and analyses, each intern leveraged their skills while simultaneously learning and growing under the mentorship of our Research team members.

Read on to learn more about each intern and the projects they worked on.

Jihyun Park

Mentor: Racquel Enad, MS, MPH, Senior Manager of Research Partnerships & Alliances

Jihyun is a master’s student in biotechnology at Columbia University. With bachelor’s degrees in both Life Sciences and Statistics, she is passionate about bridging science, data, and business. She has experience in coordinating cross-functional projects and building practical and quantitative tools that improve operational efficiency and business decision-making in the biotech and healthcare sector. In her free time, Jihyun likes to explore new favorite cafes, exercise, and play the electric guitar.

Over the summer, Jihyun worked with the Research Business Development and Partnerships team to strengthen alliance management for the Industry Development and Discovery Partnerships (IDDP) Program. She built a database of IDDP company grantees and their milestones (e.g., financings, partnerships, and clinical progress) since the program began in 2004, developed a tool the team can use to stay current on grantees’ progress after their awards, and created a visualization that maps how IDDP companies connect with one another and the broader T1D industry. Together, these resources help the team measure the program’s long-term impact and identify new opportunities to support grantees.

Sophia Meininger

Mentor: Matt Whipple, Analyst, Research Strategy

Sophia is part of an accelerated program at Binghamton University, completing a dual undergraduate degree in Global Public Health and Africana Studies, and she will begin a Master of Public Health (MPH) program this fall. Her academic work and leadership experiences have shaped a deep passion for health equity, community engagement, and advocacy. Sophia has lived with T1D since she was four years old, so contributing to Breakthrough T1D’s mission was, in her words, a genuine privilege. 

This summer, Sophia joined Breakthrough T1D’s program management team to build a global funding landscape for type 1 diabetes research. Over the course of her internship, Sophia researched the foundations, government agencies, and regional funders supporting T1D research with a focus on regions where the T1D research ecosystem is still taking shape. The landscape identified the leading institutions and investigators driving T1D research forward. Sophia presented her findings to the Research department, showing the funding dynamics in these regions and identifying opportunities for collaboration. Her work gave Breakthrough T1D a stronger foundation for continuing to be an international organization to connect researchers, funders, and the T1D community across borders.

Aliaa Elkallini

Mentor: Nicholas Mamrak, Ph.D., Senior Scientist

Aliaa is pursuing Bachelor of Science and M.D. degrees at the Sophie Davis School of Biomedical Education, which is part of the City University of New York (CUNY) School of Medicine. She’s specifically interested in understanding how scientific findings can be translated into meaningful improvements in patient care.

This summer, Aliaa joined Breakthrough T1D’s Cell Therapy team. Her work focused on the characterization of manufactured islets, which can vary significantly and make it difficult to compare data and reproduce findings. To address this gap, she reviewed published studies, identified where characterization practices were consistent or fragmented, and spoke with investigators to understand which information is most useful in practice. From this work, she developed two complementary frameworks: one focused on the minimum information needed to clearly characterize manufactured islets and another that adjusts expectations based on the purpose of the study. Together, these frameworks are meant to give Breakthrough T1D and investigators a more consistent way to evaluate new approaches, understand which information should be available, and compare the strength of the evidence when considering future research support.

Avi Patel

Mentor: Raquel Lopez Diez, Ph.D., Senior Scientist

Avi is an MPH candidate at Long Island University Brooklyn. She previously trained as a dentist in India, and her interests lie in health systems, health services research, and the policy levers that govern access and delivery. Avi brings expertise in epidemiology, biostatistics, health policy, and research methods, plus a clinician’s perspective from the point of care. Outside of work, she loves reading classic literature, cooking, and exploring the city’s art galleries and cafes.

Avi supported Breakthrough T1D’s Early Detection portfolio by conducting a global landscape and gap analysis of T1D screening programs. She designed and led a survey of international screening programs, examining how they are designed and implemented, and identified gaps and opportunities for improvement. To build a complete picture of the field, she drew on organizational records, published literature, and clinical trial registries, then validated the resulting data for accuracy.

Avi compared program methodology against international clinical consensus guidelines to assess how closely the field aligns with evidence-based screening practice, and she synthesized her findings into an executive-level presentation for organizational leadership, translating complex comparative data into clear, actionable recommendations. Her work gives Breakthrough T1D a stronger foundation for understanding the global screening landscape and identifying where to focus future early detection efforts.

Kenzie Li

Mentor: Gianna Strand, MS, Ph.D., Associate Director, Clinical Research

Kenzie is a master’s student at Weill Cornell Medicine in New York City, where she studies Biostatistics and Data Science. She is passionate about using data to tackle real healthcare challenges and to make clinical trials work better for the people who take part in them. She is also a talented artist across different mediums, including oil painting, marker drawing, and pen-and-ink illustration.

During her internship with the Clinical Research team, Kenzie played a key role in examining the real-world barriers and facilitators that clinical trial participants face. Kenzie worked on the final stages of data analysis, built visualizations, and incorporated information from a comparison study of similar trials in Europe. These results will help inform how Breakthrough T1D supports the design of more accessible, participant-centered trials in the future.

Kenzie also kicked off an ambitious new project: a landscape gap analysis mapping clinical T1D evidence across the globe from 1975 to 2026. Once complete, this map will let Breakthrough T1D pinpoint where research evidence is missing or outdated. This supports the Research team in identifying and focusing future mission-driven projects toward the populations and regions where they are needed most.

By investing time and mentorship in our interns, we’re essentially investing in up-and-coming thought leaders and emboldening them to take part in our mission. They remind us that progress toward a world without T1D depends on the people we bring into this challenge. “The summer interns bring a fresh perspective and creativity to their projects, giving us a better understanding of T1D and how to advance our mission,” explains Matt Whipple, one of this year’s mentors.

They are the next researchers, public health experts, doctors, advocates, and more that will help us accomplish our goal, now and in the future. Our interns advance Breakthrough T1D’s work today by bringing new ideas, questions, and energy that will carry the mission forward to tomorrow.

“Making progress toward our mission requires us to stay innovative, analytical, and open to learning. Training the next generation is important not only because we can help develop future leaders, but because we learn from them too. That exchange of ideas, perspectives, and curiosity helps move us closer to breakthroughs in T1D,” shares Racquel Enad, another mentor.

Thank you to our 2026 interns for their contributions, and we look forward to seeing what they will accomplish next!

In March 2026, Jaipur, India, hosted something unprecedented: the first global gathering dedicated to ending diabetes stigma and beginning to build solutions.

The inaugural Global Summit to End Diabetes Stigma welcomed 190 participants from 35 countries. More than half were living with diabetes themselves. They came not simply to describe the problem, but to chart a path toward meaningful, lasting change.

Nothing About Us Without Us—in Practice 

The Summit was built around a simple but powerful principle: #NothingAboutUsWithoutUs. 

That’s not a slogan. It shaped every aspect of the event. 

The 16-member Steering Committee represented 10 countries, with 11 members bringing lived experience of diabetes. On the Summit’s opening day, participants calculated that the room represented more than 1,300 cumulative years of lived and loved experience with diabetes—a powerful reminder that the people most affected by diabetes stigma are also best equipped to help solve it. 

Ensuring diverse voices were present was equally important. Eighty-five delegates attended through full #dedoc° travel scholarships made possible by Breakthrough T1D and several industry sponsors. Nearly nine in ten scholarship recipients had lived experience of diabetes, and more than 60% came from low- and middle-income countries. For many, it was their first international conference. For some, it was their first time traveling internationally. 

Guiding conversations throughout the event was Renza Scibilia, Breakthrough T1D’s Senior Director for Global Responsibility and one of the Summit’s emcees. A longtime advocate for the Language Matters movement, she helped facilitate discussions rooted in both lived expertise and real life with T1D. 

From Stories to Solutions

“We weren’t talking about people with diabetes—we were talking as people with diabetes.” 

-Renza Scibilia 

Across two days, participants gave voice to the many ways diabetes stigma shows up in everyday life. They spoke about being blamed for a diagnosis they did not cause. About language that diminishes rather than empowers. About navigating healthcare systems, workplaces, schools, and communities where a medical condition is too often misunderstood as a personal failing. 

These experiences are far from isolated. According to research published in The Lancet, four in five people living with diabetes report experiencing stigma, and one in three report discrimination. 

What made this Summit different was what happened next. The Summit began with stories. It ended with evidence, commitments, and a shared commitment to creating a roadmap for action.  

Together, participants explored opportunities to improve language, strengthen healthcare, influence public awareness campaigns, advance policy, and elevate diabetes stigma within international human rights frameworks. 

The Summit concluded with an agreement to turn ideas into commitments, reinforcing that meaningful progress depends not only on conversation, but on sustained action. 

A Beginning, Not a Conclusion

The Global Summit represented the next step: from commitment to coordinated action. 

No single meeting can end diabetes stigma. 

But the Global Summit marked an important turning point. 

A global roadmap for action is now being co-designed, informed by the evidence shared in Jaipur and the commitments participants made together. The work will continue across countries, organizations, and communities, building on the momentum created by this first gathering. 

For Breakthrough T1D, the Summit reinforced a belief that guides our work around the world: the most meaningful progress on access, equity, and care happens when people with lived experience are not simply represented—they are trusted to lead. 

The conversations in Jaipur have ended. 

The movement they strengthened is only beginning. 

For more information, including key outcomes and ongoing initiatives, visit the End Diabetes Stigma website. 

For more information about Breakthrough T1D’s global initiatives, visit Our Global Presence and ALIGN-T1D.